USANA Health Sciences, Inc. (NYSE:USNA) Insider David Mulham Mulham Sells 3,234 Shares

USANA Health Sciences, Inc. (NYSE:USNA) insider David Mulham Mulham sold 3,234 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $32.98, for a total value of $106,657.32. Following the sale, the insider now owns 12,775 shares of the company’s stock, valued at approximately $421,319.50. The trade was a 20.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

USANA Health Sciences Trading Down 0.0 %

Shares of NYSE USNA opened at $33.07 on Wednesday. The firm’s 50-day moving average price is $32.92 and its 200-day moving average price is $36.13. USANA Health Sciences, Inc. has a 1-year low of $27.71 and a 1-year high of $50.32. The firm has a market capitalization of $630.24 million, a P/E ratio of 11.68, a P/E/G ratio of 0.93 and a beta of 0.98.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $0.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.15. The firm had revenue of $213.61 million during the quarter, compared to analysts’ expectations of $208.82 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. Equities research analysts forecast that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on USNA. DA Davidson decreased their price target on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating for the company in a report on Thursday, February 27th. StockNews.com lowered shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th. Finally, Sidoti lowered shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. R Squared Ltd acquired a new position in shares of USANA Health Sciences during the fourth quarter valued at about $28,000. Safe Harbor Fiduciary LLC acquired a new position in shares of USANA Health Sciences during the third quarter valued at about $30,000. KBC Group NV grew its holdings in shares of USANA Health Sciences by 96.6% during the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after buying an additional 519 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of USANA Health Sciences in the fourth quarter valued at about $83,000. Finally, Quantbot Technologies LP purchased a new stake in shares of USANA Health Sciences in the fourth quarter valued at about $132,000. 54.25% of the stock is currently owned by institutional investors and hedge funds.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.